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ABSTRACT: Despite increasing evidence that supports the
role of different post-translational modifications (PTMs) in
modulating α-synuclein (α-syn) aggregation and toxicity,
relatively little is known about the functional consequences
of each modification and whether or not these modifications
are regulated by each other. This lack of knowledge arises
primarily from the current lack of tools and methodologies for
the site-specific introduction of PTMs in α-syn. More specifically, the kinases that mediate selective and efficient phosphorylation
of C-terminal tyrosine residues of α-syn remain to be identified. Unlike phospho-serine and phospho-threonine residues, which
in some cases can be mimicked by serine/threonine→ glutamate or aspartate substitutions, there are no natural amino acids that
can mimic phospho-tyrosine. To address these challenges, we developed a general and efficient semisynthetic strategy that
enables the site-specific introduction of single or multiple PTMs and the preparation of homogeneously C-terminal modified
forms of α-syn in milligram quantities. These advances have allowed us to investigate, for the first time, the effects of selective
phosphorylation at Y125 on the structure, aggregation, membrane binding, and subcellular localization of α-syn. The
development of semisynthetic methods for the site-specific introduction of single or PTMs represents an important advance
toward determining the roles of such modifications in α-syn structure, aggregation, and functions in heath and disease.
■ INTRODUCTION
α-Synuclein (α-syn) aggregation and fibrillogenesis in the brain
are the hallmark of Parkinson’s disease (PD) and have been
linked to the pathogenesis of several neurodegenerative diseases
that are collectively referred to as “synucleinopathies”.1 PD is
characterized by the formation of intraneuronal inclusions
termed Lewy bodies (LB), which are composed primarily of
insoluble fibrillar and aggregated forms of α-syn.2,3 Although
three mutations in the α-syn gene (A30P,4 A53T,5 and E46K6)
have been linked to early-onset forms of the disease, they
account for only 1% of all PD cases. Therefore, a better
understanding of the molecular determinants that govern the
structural, aggregation, and functional properties of α-syn is
crucial to elucidating its role in the pathogenesis of sporadic
and inherited forms of PD.
The primary sequence of α-syn can be divided into three
domains, which are the following: (1) The N-terminal domain
which contains the sites of the three disease-associated
mutations and the imperfect 11 repeats of a conserved
sequence (KTKEGV) that play an important role in regulating
α-syn secretion,7 internalization,8,9 and binding to membranes.
(2) The central fragment, also known as NAC (non-amyloid
beta component) (residues 61−95) region, is highly hydro-
phobic and is essential for α-syn oligomerization and
fibrillogenesis.10 (3) The C-terminal region comprising residues
96−140. This region is highly disordered and negatively
charged (10 glutamate and 5 aspartate residues). The C-
terminal region has been proposed to play a role in regulating
α-syn transport to the nucleus and has been shown to mediate
α-syn interactions with other proteins,11−14 metal ions,15,16 and
natural ligands (e.g., dopamine and polyamines).17 The
majority of α-syn PTMs (truncation, phosphorylation,
methionine oxidation, and nitration) occurs within the C-
terminal region. The clustering of PTMs in this functional
domain of the protein suggests that these modifications may be
involved in the regulation of α-syn function in health and
disease. This hypothesis is further supported by the fact that the
majority of these post-translational modification sites are highly
conserved across different species. Furthermore, the close
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proximity of these different modifications suggests that they
may act in concert, and cross-talk between these modifications
may constitute an additional molecular switch for regulating the
dynamics of α-syn function and aggregation (Scheme 1).
Despite mounting evidence supporting the role of C-terminal
phosphorylation in modulating α-syn aggregation and toxicity,
relatively little is known about the functional consequences of
tyrosine phosphorylation and whether or not tyrosine and
serine phosphorylation in this region are regulated by each
other.18 This is partly due to the lack of tools and
methodologies for the site-specific introduction of single or
multiple PTMs in α-syn. Previously, our group identified the
polo-like kinases, PLK2 and PLK3, which phosphorylate α-syn
efficiently in vitro as major contributors to α-syn phosphor-
ylation in vivo.19,20 However, the kinases that carry out selective
and efficient phosphorylation of the other known and putative
phosphorylation sites (S87, Y125, Y133, and Y136) remain to
be identified.
Protein semisynthesis,21−28 which combines the powers of
recombinant protein expression, peptide chemical synthesis,
and native chemical ligation (NCL), has been successfully used
to study post-translational modifications on a variety of
proteins27,29 and offers a means of generating site-specifically
modified forms of α-syn30,31 (Scheme 2). To address the
aforementioned challenges and to facilitate the investigation of
the structural and functional consequences of specific C-
terminal PTMs of α-syn, we developed a general and efficient
semisynthetic strategy that permits the site-specific introduction
of single or multiple PTMs. This strategy also enables the
preparation of milligram quantities of homogeneous forms of α-
syn modified at the C-terminus that are sufficient for carrying
out detailed biochemical, biophysical, and cellular studies. We
used this strategy to produce α-syn phosphorylated at tyrosine
125 (pY125 α-syn). We chose to investigate Y125 phosphor-
ylation for the following reasons: (1) The levels of pY125 α-syn
have been reported to decrease with age.18 (2) Studies by
Feany and colleagues suggest that phosphorylation at Y125 acts
as a counter-regulator of pS129-induced toxicity in the fly
model of PD,18 and provide evidence for a potential cross-talk
between these two modifications. (3) There are no effective
mutagenesis-based strategies for mimicking tyrosine phosphor-
ylation, and thus, very little is known about the structural and
functional consequences of selective phosphorylation of α-syn
at Y125. More specifically, we determined the effect of
phosphorylation at Y125 on the structure, fibril formation,
and phospholipid membrane-association-induced conforma-
tional shifts in vitro. In addition, we further probed cross-talk
between phosphorylation at S129, Y125, and S87 residues by
determining the relative activity of each phosphorylated form of
Scheme 1. Clustering of C-Terminal Post-Translational
Modifications of α-Syna
a(A) Schematic depiction of the sequence of α-syn with its 3 domains.
The putative and identified sites of C-terminal phosphorylation are
indicated with arrows. (B) Sequence alignment of the sequences of the
C-terminal domain of α-syn from 5 different species. The conserved
positions of the phosphorylation sites are highlighted in red.
Scheme 2. Mechanism of Native Chemical Ligationa
aTop: A peptide thioester and a peptide fragment bearing an N-terminal Cys undergo a thioester exchange followed by an S to N acyl migration to
create an amide bond between two unprotected peptides in aqueous solution. Bottom: Semisynthetic strategy to generate derivatives of α-syn site-
specifically phosphorylated within the C-terminal region. The protein thioester α-syn(1−106)SR generated by recombinant protein expression is
ligated by NCL to the synthetic C-terminal fragment α-syn(A107C−140) bearing the desired phosphorylated side chain. A final desulfurization step
restores the native Ala-107.
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α-syn as a substrate for the kinases that phosphorylate α-syn at
other residues within the C-terminus. We also assessed, for the
first time, the subcellular localization of pY125 α-syn in
mammalian cells and rat hippocampal neurons. Our work
demonstrates the power and potential of applying chemical
approaches to elucidate the role of C-terminal PTMs in
regulating α-syn function in health and disease.
■ MATERIALS AND METHODS
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc)-amino acids, t-
butyloxycarbonyl (Boc)-amino acids, and 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were pur-
chased from Novabiochem or Anaspec. The side-chain functionalities
of the Fmoc-amino acids were chemically protected as shown in
parentheses: Asp(OtBu), Glu(OtBu), Lys(Boc), Thr(tBu), Ser(tBu),
Tyr(tBu), Gln(Trt), and Asn(Trt). Phosphorylated Tyr residues were
purchased from Novabiochem or Anaspec as protected Fmoc-
Tyr[PO(OBzl)]−OH building blocks. All unlisted amino acids were
not protected. The Boc-amino acid was Boc-Cys(Trt). N,N-
Diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), triiso-
propylsilane (TIPS), sodium 2-mercaptoethanesulfonate (MESNa),
ammonium iodide, 1,2-ethanedithiol (EDT), 2-methyl-2-propanethiol
(tert-butyl mercaptan, tBuSH), dimethylsulfide, guanidine hydro-
chloride (GuHCl), and tris(2-carboxyethyl)-phosphine hydrochloride
(TCEP) were purchased from Sigma-Aldrich. Piperidine and diethyl
ether were purchased from Acros. 2-2′-Azobis[2-(2-imidazolin-2-
yl)propane] dihydrochloride (VA-044) was purchased from Wako.
The solvents N-methylpyrrolidone (NMP), dichloromethane, and
HPLC-grade acetonitrile were purchased from VWR.
General Solid Phase Peptide Synthesis and Purification.
Solid phase peptide synthesis was performed on an automated CS
336X peptide synthesizer from CS Bio using standard Fmoc protocols
including the in situ neutralization protocol described by Alewood and
colleagues.32 A preloaded Fmoc-Ala Wang resin was used. Syntheses
were carried out on a 0.2 mmol scale, and coupling steps were
performed with 5 equiv of Fmoc-amino acid, 5 equiv of HBTU/HOBt,
and 5 equiv of DIPEA in NMP. The N-terminal Cys residues were
attached with Boc protecting groups on their N-terminus. Fmoc-group
deprotections were carried out with 20% piperidine in DMF. Peptide
side chain deprotections, removal of N-terminal Boc group, and
cleavage from the resin were performed by treatment with 81.5/5/3/
5/2.5/2/1.5 of TFA/water/phenol/thioanisole/EDT/Me2S/NH4I for
4 h on a rotating wheel to generate peptides with a C-terminal acid
functionality. The crude product was subsequently precipitated three
times with a 10-fold excess volume of cold diethyl ether, dissolved in
water, and lyophilized. Peptides were then purified by reverse-phase
HPLC (Waters 600 system) using a Cosmosil C18 preparative column
(20 mm × 250 mm, 5 μm particles, 300 Å pores) with a linear gradient
of 20−70% B over 30 min (solvent A was water/0.1% TFA and
solvent B was acetonitrile/0.1% TFA). Peptide elution was monitored
by UV absorbance at 214 and 280 nm. Peptide masses were confirmed
by MALDI-TOF-MS and ESI-MS analysis. Peptide purity was
confirmed by reinjection on an analytical RP-HPLC column
(Cosmosil C18, 4.6 mm × 250 mm, 5 μm particles, 300 Å pores).
Expression and Purification of Recombinant α-Syn(1−
106)SR. C-terminally truncated human α-synuclein was initially
cloned into the pT7-7 vector in fusion with the GyrA Mini-Intein
from Mycobacterium Xenopii and a chitin binding domain (CBD) using
the following primers: forward 5′-GGG CAA GAA TGA AGA AGG
ATG CCG AAG AGC AGG AAT TCT G-3′, and reverse 5′-CAG
AAT TCC TGC TCT TCG GCA TCC TTC TTC ATT CTT GCC
C-3′. The α-syn fragment (1−106) was isolated by NdeI and SapI
digest. The intein was isolated from the pTXB1 vector (New England
Biolabs) by SapI and BamHI digest. Both fragments were ligated into
pT7-7 digested by NdeI and BamHI to generate the plasmid pT7-7 α-
syn-Mxe-CBD. To insert a polyhistidine tag at the C-terminus of the
intein instead of CBD, an EcoRI site was introduced using site-directed
mutagenesis using the following primers: forward 5′ CTG GCC TCA
CCG GTC TGG AAT TCG GCC TCA CGA CAA ATC 3′, and
reverse 5′ GAT TTG TCG TGA GGC CGA ATT CCA GAC CGG
TGA GGC CAG 3′. An oligonucleotide containing six histidines and
two stop codons with the digested recognition sequences of EcoRI and
BamHI sites was ordered: forward 5′AA TTC CAC CAC CAC CAC
CAC CAC TGA TAA G 3′, and reverse 5′ GA TCC TTA TCA GTG
GTG GTG GTG GTG GTG G 3′. The annealed oligonucleotides
were ligated into the plasmid pT7-7 α-syn-Mxe-CBD digested with
EcoRI and BamHI. Expression was carried out in E. coli BL21(DE3).
Protein expression was induced with 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and by growing the cells for 4 h at
37 °C. The cells were harvested by centrifugation and lysed by
ultrasonication in 40 mM Tris-acetate, 5 mM EDTA pH 8.3. The
supernatant was separated from the cell debris by centrifugation (23
000g, 30 min, 4 °C). MgCl2 (4 equiv) was added prior to the loading
on the Ni-NTA column. The soluble fraction was loaded on a HisPrep
FF 16/60 (Amersham) pre-equilibrated with 50 mM HEPES pH 7.5.
A washing step of 50 mM HEPES 25 mM imidazole, pH 7.5 for 5
column volumes was included to remove nonspecific binding. The
protein α-syn-Mxe-His(6) was eluted with a step elution of 50 mM
HEPES, 350 mM Imidazole pH 7.5. The splicing reaction was carried
out directly in the eluate from the Ni-NTA column for 12 h under
agitation at RT in presence of 0.25 M MESNa. The splicing efficiency
was around 90% (by SDS-PAGE analysis, data not shown). The
sample was subsequently purified by reverse-phase HPLC using a
preparative C4 column (VYDAC, 20 mm × 250 mm, 5 μm particles,
300 Å pores) with a linear gradient of 20−70% B in 30 min at a flow
rate of 10 mL/min (solvent A was water/0.1% TFA and solvent B was
acetonitrile/0.1% TFA). The pure protein thioester was obtained in a
yield of 10 mg/L of BL21 (DE3) expression medium.
Expression and Purification of 15N Labeled Proteins. α-Syn
A107C. The α-syn mutant A107C was generated using single-
point mutagenesis with the following primer pairs to generate
the plasmid pT7-7 α-syn A107C: forward primer 5′ GCA AGA
ATG AAG AAG GAT GCC CAC AGG AAG GAA TTC TG 3′
and reverse primer 5′ CAG AAT TCC TTC CTG TGG GCA
TCC TTC TTC ATT CTT GC 3′. BL21 (DE3) cells were
transformed with the plasmid and grown in M9 minimal media
with 15N labeled ammonium chloride. Protein expression was
induced by the addition of 1 mM IPTG for 4 h at 37 °C. After
cell harvest by centrifugation at 6000g for 15 min, the cell pellet
was resuspended in 40 mM Tris-acetate and 5 mM EDTA (pH
8.3) and lysed by ultrasonication. The insoluble material was
removed by centrifugation at 23 000g for 40 min at 4 °C. The
supernatant was boiled for 15 min in a water bath at 100 °C
followed by centrifugation at 23 000g for 40 min, which
precipitates most cellular proteins but not α-syn A107C. The
final supernatant was filtered through a PVDF membrane with
0.22 μm pores. Anion-exchange chromatography was per-
formed on a Pharmacia AKTA FPLC system using a 20 mL
HiPrep 16/10 Q FF column (Amersham). The protein was
eluted with a linear gradient of 0−1 M NaCl (the protein elutes
at approximately 300 mM NaCl) and subsequently purified on
a Superdex 200 26/60 size-exclusion chromatography column
(Amersham) using a mobile phase of buffer containing 50 mM
Tris, 150 mM NaCl, pH 7.5. The purified protein was dialyzed
extensively against deionized water and lyophilized and stored
at −20 °C until used. From 1 L of expression medium, the
average yield of lyophilized material was 30 mg. To remove the
glutathatione disulfide adduct, the lyophilized powder was
dissolved in a buffer containing 50 mM Tris 150 mM NaCl
(pH 7.5), with 30 equiv of TCEP, and the solution was
incubated for 10 min at RT. The protein was subsequently
purified on a C4 preparative column (Vydac) with a linear
gradient of 20−70% B in solvent A over 30 min at a flow rate of
10 mL/min (solvent A was water/0.1% TFA and solvent B was
acetonitrile/0.1% TFA). The N15 labeled protein was obtained
in a final yield of 10 mg/L of bacterial expression.
α-Syn (1−106)SR. The expression of 15N labeled α-syn(1-106) SR
was carried out in a similar manner as for the nonlabeled protein with
an overall yield of pure protein of ∼3.5 mg/L.
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Semisynthesis and Desulfurization of α-Syn Phosphorylated
at Tyr 125. The semisynthesis of α-syn WT or site-specifically
phosphorylated within the C-terminus (residues 107−140) involved
an NCL reaction between recombinant α-syn(1−106)SR and
synthetic peptides α-syn (A107C−140) phosphorylated at Tyr-125
or the WT peptide. NCL reactions were carried out in 6 M GuHCl,
200 mM sodium phosphate buffer, pH 7.0, using 1.5 mM of α-syn(1−
106)SR and 2 molar excess of C-terminal peptide A107C−140 pY125
or A107C−140 WT peptide in the presence of 30 equiv of TCEP in a
volume of 1 mL at 37 °C with shaking at 1000 rpm. Three ligation
reactions were carried out in parallel. For monitoring the NCL
reactions, aliquots of the reaction mixture (4 μL) were removed and
quenched with 38 μL of water containing 0.1% TFA and subsequently
analyzed by SDS-PAGE (15% polyacrylamide) and MALDI-TOF-MS.
RP-HPLC was not used due to the coelution of α-syn(1−106)SR and
the ligated product under all conditions tested in our laboratory. On
the basis of SDS-PAGE analysis, the desired ligated product was
produced within 1−2 h.
Free-radical-based desulfurization of the semisynthetic α-syn mutant
was carried out as previously described by Danishefsky and
colleagues.33 In our case, the ligation and the desulfurization were
carried out in one pot. A 1 mL sample of a solution of 1 M of TCEP
(in 6 M GuHCl, 200 mM sodium phosphate pH 7.0) was added to the
ligation reaction. A 160 μL sample of 2-methyl-2-propanethiol and 100
μL of a 0.1 M solution of 2-2′-azobis[2-(2-imidazolin-2-yl)propane]
dihydrochloride (VA-044) free radical initiator (in 6 M GuHCl, 200
mM sodium phosphate pH 7.0) were added under argon. The reaction
was incubated at 37 °C with agitation at 1000 rpm in a ventilated fume
hood for 3.5 h. The progress of desulfurization was followed by
MALDI-TOF-MS.
Purification of the Semisynthetic pY125 α-Syn. Prior to
purification, the ligated desulfurized products from the 3 ligation/
desulfurization reactions (that were carried out in parallel) were
desalted through a 5 mL HiTrap desalting column (Amersham) with
20 mM sodium dihydrogen citrate pH 4.0 as the mobile phase. The
fractions containing the protein were subsequently pooled and
manually injected on a 5 mL cation-exchange column HiTrap SP
HP (Amersham). We took advantage of the charge difference between
the full-length protein, the fragment α-syn(1−106)OH (hydrolyzed
thioester), and the C-terminal 107−140 peptide for a single-column
purification. At pH 4.0, the peptide is negatively charged (net charge
−2) and will not bind to the column while the full-length protein and
the fragment (1−106) are positively charged and hence will bind to
the column. At pH 5.0, the charge of the full-length protein is −1, and
the fragment (1−106) has a charge of 6 and can be subsequently
separated using a gradient of salt. We initially allow the peptide to pass
in the flow through by washing the column after injection with 10
column volumes (CV) of 20 mM sodium citrate pH 4 and then with a
linear gradient of NaCl from 0 to 100% B (where A is a solution of 20
mM sodium citrate pH 4, B the same solution supplemented with 0.5
M NaCl) over 4 CV on an Akta Purifier system. To elute bound
proteins, we applied a linear gradient of NaCl from 0 to 70% B (where
A is a solution of 20 mM sodium citrate pH 5 and B is the same
solution supplemented with 0.25 M NaCl) over 30 CV at a flow of 1
mL/min. The full-length protein elutes around 20% B and the
fragment (1−106) around 30% B. The fractions containing the protein
were extensively dialyzed against deionized water and lyophilized. The
final yield of pure lyophilized protein is around 19% (9 mg).
Preparation and Purification of pS129 and pS87 α-Syn.
Recombinant WT α-syn (3 mg per reaction, 10 μM) was
phosphorylated at S129 in vitro by PLK3 (10 μg per reaction, 4.8
μg/mL) at 30 °C in 20 mM HEPES (pH 7.4), 10 mM MgCl2, 2 mM
DTT, and 1 mM ATP. The phosphorylated protein was purified by
reverse-phase HPLC using a semipreparative C8 column (InertSil 7.6
mm × 250 mm, 5 μm particles, 300 Å pores). The proteins were
eluted with a linear gradient from 20% to 40% of solvent B in solvent
A over 40 min at a flow rate of 5 mL/min (solvent A was water/0.1%
TFA, and solvent B was acetonitrile/0.1% TFA). The collected
fractions were pooled according to purity assessed by ESI-MS and
MALDI-TOF-MS. After purification, pS129 α-syn was lyophilized and
stored at −20 °C until use. pS87 α-syn was prepared as previously
described.34
Circular Dichroism Measurements. Protein samples (10 μM) in
pH 7.5 buffer containing 50 mM Tris buffer and 150 mM NaCl were
analyzed at 25 °C using a Jasco J-815 CD spectrometer. An average of
10 spectra was collected in the range of 195−250 nm using a 1.0 mm
path length quartz cuvette. Data points were acquired every 0.2 nm in
the continuous scanning mode at a speed of 50 nm/min with a digital
integration time of 2 s, and a bandwidth of 1 nm. Processed spectra
were obtained by subtracting the baseline signal due to the buffer and
cell contribution from the protein spectra, and a final smoothing was
applied (Savitzky-Golay filter; convolution width of 25 data points).
In Vitro Phosphorylation Assay. pY125 α-syn (6 μM) was
incubated in 50 mM Tris pH 7.5, 10 mM DTT, 1 mM ATP, 1 mM
MgCl2 in the presence of 0.42 μg (1 μL) of PLK3 (Invitrogen) in a
total volume of 50 μL. For the phosphorylation by CK1, 6 μM of
protein were incubated in CK1 buffer 1× supplemented with 1 mM
ATP and 1000 units of CK1 (1 μL) in a final volume of 50 μL. The
reaction was allowed to proceed for 12 h at 30 °C with no agitation.
The extent of phosphorylation was monitored by MALDI-TOF-MS
and western-blotting using pS87-, pS129-, and pY125-specific
antibodies.
For phosphorylation by tyrosine kinases, WT α-syn, -pS87, and
-pS129 were incubated at a concentration of 3 μM in a final volume of
30 μL with the appropriate tyrosine kinase. Kinases were added at a
final concentration of 50 nM. The reaction buffers were the following:
Syk/Lyn, 50 mM Tris and 5 mM MnCl2 (50 μL); Fyn/Src, 20 mM
Tris and 5 mM MnCl2 (pH 7.4); Fgr, 50 mM Tris and 5 mM MgCl2
(pH 7.5). The reactions were started by the addition of freshly
prepared ATP (1 mM), and incubated for 14 h at 30 °C before
analysis.
NMR Spectroscopy. NMR studies were performed as previously
described.35 Briefly, lyophilized 15N-labeled α-syn was dissolved in
sample buffer (100 mM NaCl, 10 mM Na2HPO4, in 90% H2O, 10%,
D2O at pH 7.4 to a concentration of 0.1−0.3 mM). For spectra in the
presence of SDS, the sample buffer also contained 40 mM SDS. All
1H, 15N HSQC spectra were collected at 10 °C in the absence of SDS
and at 40 °C in the presence of SDS on either a Varian INOVA 600
MHz spectrometer (Weill Cornell Medical College) or a Bruker
Avance 800 MHz spectrometer (New York Structural Biology Center)
equipped with cryogenic probes. NMR data were processed by
NMRPipe36 and analyzed in NMRViewJ.37 Spectra were referenced
indirectly to sodium 2,2-dimethyl-2-silapentane-5-sulfonate and
ammonia using the known chemical shift of water. Assignments for
the spectra of mutant and phosphorylated α-syn at Y125 were
estimated by transferring each previously assigned cross-peak in the
HSQC spectrum of WT α-syn to the closest unassigned cross-peak in
each spectrum. Normalized per residue, the chemical shift change was
calculated as Δδ = √(ΔδH12 + ΔδN152/25)/2. For PRE experiments,
α-syn was dissolved in sample buffer without SDS, a 10-fold excess of
MTSL spin-label was added, and the resulting solution was incubated
for 30 min. A buffer-exchange column was used to remove unbound
spin-label, and the sample was divided into diamagnetic and
paramagnetic samples. DTT (final concentration 2 mM) was added
to the diamagnetic sample to reduce off the spin-label. Matched two-
dimensional HSQC spectra were collected on the two samples, and
the ratio of the intensity of each cross-peak was determined.
In Vitro Fibrillization Assay. pY125 α-syn and WT α-syn were
incubated at 15 μM in a volume of 450 μL under constant agitation at
1200 rpm for 48 h or 7 days at 37 °C. ThT fluorescence reading was
carried out with a ThT concentration of 10 μM and a protein
concentration of 1.5 μM in a volume of 70 μL in a pH 8.5 buffer
containing 50 mM glycine. A TECAN spectrometer was used to
measure ThT fluorescence at an excitation wavelength of 450 nm and
an emission wavelength of 485 nm. Aliquots taken at 0, 24, and 48 h
were measured in triplicate. Values were expressed as the ThT
fluorescence of three measurements (mean ± SD).
Transmission Electron Microscopy (TEM). Proteins as 7 μL
samples were deposited on Formvar-coated 200 mesh copper grids
(Electron Microscopy Sciences). Grids were washed with two drops of
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double-distilled H2O and stained with two drops of freshly prepared
2% (w/v) uranyl acetate (Electron Microscopy Sciences) and then
vacuum-dried from the edge of the grids. Specimens were viewed on a
Philips CIME 12 electron microscope, operated at 80 kV. Digitized
photographs were recorded with a CCD camera (Digital Camera
Morada by Soft Imaging System, 4008 × 2672 pixels).
Western-Blot Analysis. Protein samples were separated at 80 V
on 15% polyacrylamide 1 mm-thick gels over 1−2 h. The proteins
were transferred onto nitrocellulose membranes (Omnilab SA) using a
semidry transfer system (Bio-Rad) under constant current (∼200 mA
per membrane), and the membranes were blocked for 1 h at room
temperature with Odyssey blocking buffer (Li-COR Biosciences)
diluted 3-fold in PBS buffer. The membranes were probed with the
relevant primary antibodies overnight at 4 °C: mouse anti-α-syn
(1:1000 dilution, BD Transduction Laboratories), rabbit anti-α-syn
ab51252 (1:1000 dilution, Abcam), rabbit anti-α-syn SA3400 (1:1000
dilution, Biomol), mouse monoclonal antiphosphorylated α-Syn at
Tyr-125 (1:1000 dilution; BD Transduction Laboratories), homemade
rabbit anti-pY125 α-syn (1:1000), mouse monoclonal anti-pS129 α-
syn (dilution 1:5000; Wako), and rabbit anti-pS87 α-syn (1:200
dilution,38). After three washes with PBS buffer containing 0.1% (v/v)
Tween 20 (Fluka), the membrane was incubated with secondary goat
antimouse or antirabbit antibodies conjugated to Alexa 680 (dilution
1:5000; Invitrogen). The membranes were then washed three times
with PBS buffer containing 0.01% (v/v) Tween 20 and once with PBS
buffer and scanned on a LiCOR scanner at 700 nm.
pY125 α-Syn Dephosphorylation Assay. HeLa cells were
grown to 90% confluency in a 10 cm Petri dish and lysed by occasional
vortexing on ice over 30 min in 600 μL of lysis buffer (50 mM tris pH
7.4, 150 mM NaCl, 5% glycerol, 25 mM sucrose, 1% NP-40, and
0.25% sodium deoxycholate with 100 mM PMSF and protease
inhibitor cocktail from Sigma). The lysate was clarified by
centrifugation at 20 800g for 30 min at 4 °C. Incubation of pY125
α-syn (1.2 μg in 100 μL) with HeLa lysate was carried out for 0, 30
min and 1 h at 37 °C. The reaction was quenched by the addition of
Laemmli sample buffer. For inhibition by sodium orthovanadate,
different concentrations of the activated inhibitor (0.1, 1, and 10 mM)
were incubated with samples of lysate containing 1.2 μg of pY125 α-
syn for 2 h. Lysate from each incubation (300 ng) was loaded onto a
SDS-PAGE gel and analyzed by western-blot with antibodies against
WT α-syn and pY125 α-syn .
Cell Culture and Transient Transfection. Human embryonic
kidney cells (HEK 293T) and HeLa cells were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum and 5% penicillin/streptomycin in a humidified
incubator with 5% CO2 at 37 °C. For HEK 293T cells, transient
transfection was performed in 6-well plates at a cell confluence of 70−
80%, using a standard calcium phosphate (CaPO4) transfection
protocol. For HeLa cells, transient transfection using Lipofectamine
2000 (Invitrogen) was performed according to the manufacturer’s
instructions. The total amount of plasmid used in the transfection was
2 μg/well for 6-well-plates and 0.8 μg/well for 24-well plates.
Detection of pY125 α-Syn in HEK 293T and HeLa Cells. HeLa
and HEK 293T cells were grown in 6-well-plates and transfected with
the plasmid pAAV α-syn WT and pAAV α-syn Y125F. The cells were
treated with pervanadate (100 μM sodium orthovanadate and 4 mM
H2O2) 24 h post-transfection for 5, 10, and 20 min, as reported
previously.39 The medium containing the inhibitor was removed, and
the cells were subsequently harvested by pipetting in PBS or by
scraping. The cells were pelleted by centrifugation at 100 g for 3 min,
lysed by the addition of 100 μL of Laemmli buffer, and boiled at 95 °C
for 30 min. A 30 μL sample was loaded on SDS-PAGE and analyzed
by western-blot with antibodies for WT α-syn and pY125 α-syn
Subcellular Fractionation. HEK 293 cells were grown in 6-well-
plates, transfected with the plasmid pAAV WT α-syn and treated with
pervanadate (100 μM sodium orthovanadate and 4 mM H2O2) 24 h
post-transfection. Subcellular fractionation was carried out using the
kit from Calbiochem according to the manufacturer’s instructions and
as previously described.38 Pervanadate (100 μM sodium orthovanadate
and 4 mM H2O2) was also added during the extraction steps.
Primary Neuronal Cultures. Rat primary neurons were cultured
from newborn Sprague−Dawley (SD) rat hippocampus, following the
regulations of Peking University Animal Care and Use Committee. In
brief, rat hippocampal tissues were dissociated with 0.25% trypsin
(Invitrogen), which was then inactivated by 10% decomplemented
fetal bovine serum (FBS, HyClone). The mixture was triturated
through a pipet to produce a homogeneous mixture. After the mixture
was filtered through 0.7 μm sterilized filters, the flow-through was
centrifuged. The pellet was then washed once with PBS followed by
one wash with Dulbecco’s modified eagle medium (DMEM) in Earle’s
balanced salt solution containing 0.225% sodium bicarbonate, 1 mM
sodium pyruvate, 2 mM L-glutamine, 0.1% dextrose, and antibiotic
Pen-Strep with 5% FBS (all from Invitrogen). Cells were then plated
on poly-L-lysine (Sigma) coated plates or on glass coverslips at a
density of 1 × 106 cells/mL. Neurons were incubated at 37 °C in
DMEM without phenol red with 5% FBS and 5% circulating CO2.
Cytarabine was added to culture media 24 h after plating to a final
concentration of 10 μM to inhibit cell growth. The culture medium
was changed every 48 h. Cells were used for experiments at day 7 of
culture.
Subcellular Localization of pY125 α-Syn in HeLa Cells. HeLa
cells were seeded on coverslips (100 000 cells in a 24-well-plate)
precoated for 30 min at RT with poly-L-lysine. The cells were
transfected with the plasmid pAAV α-syn WT (0.8 μg) and
subsequently treated with pervanadate prepared as described above
for 30 min 24 h post-transfection. The cells were subsequently fixed in
4% paraformaldehyde in PBS for 30 min, washed three times in PBS,
blocked for 1 h with 3% BSA, 0.1% Triton X-100 in PBS, and
incubated overnight at 4 °C with a cocktail of primary antibodies
(mouse α-syn pY125, BD Pharmingen, 558246, 1:1000; rabbit α-syn,
ab51252, Abcam, 1:1000) in 1% BSA, 0.1% Triton X-100 in PBS. The
cells were then washed three times with 1% BSA, 0.1% Triton X-100 in
PBS, and incubated for 1 h at RT with a cocktail of secondary
antibodies (goat antimouse coupled to Alexa Fluor 568, Molecular
Probes Inc., 1:1000; goat antirabbit coupled to Alexa Fluor 488,
Molecular Probes Inc., 1:1000). After three washes in PBS, coverslips
were counter-stained with 4,6-diamidino-2-phenylindole (DAPI,
1:5000), washed 3 times with PBS, and mounted on glass slides
with Vectashield mounting medium (Vector). Cells were imaged using
a Zeiss LSM700 confocal microscope.
Microinjection and Immunocytochemistry. Thin-walled bor-
osilicate glass capillaries (outer diameter = 1.0 mm, inner diameter =
0.5 mm) with a microfilament (MTW100F-4, World Precision
Instrument) were pulled with a Flaming/Brown micropipet puller
(P-97, Sutter) to obtain injection needles with a tip diameter of
approximately 0.5 μm. Microinjections into the cytosol of each cell
were performed using an Eppendorf microinjector FemtoJet and
Eppendorf micromanipulator (Eppendorf). Neurons were injected
with 25 fl/shot at an injection pressure of 100 hPa, a compensation
pressure of 50 hPa, and an injection time of 0.1 s. pY125 α-syn was
diluted for a final concentration of 1 μM in phosphate-buffered saline
(PBS, 0.14 M NaCl, 0.003 M KCl, 0.01 M Na2HPO4, 0.002 M
KH2PO4, pH7.2). The solutions were injected with 100 μg/mL
dextran Texas Red (DTR, MW: 3000, Molecular Probes) as a
fluorescent marker or with Fast Green as a visible marker to enable the
identification of injected cells. The injected cells were treated either
with control DMEM medium or with pervanadate (100 μM
orthovanadate and 4 mM H2O2) for 30 min. For immunocytochem-
istry, cells were fixed, permeabilized, and blocked with 10% donkey
serum at room temperature followed by incubation with anti-α-
synuclein antibody (mouse α-syn pY125, BD Pharmingen, 558246,
1:1000; rabbit α-syn, ab51252, Abcam, 1: 1000) at 4 °C for 24 h. Cy2-
or Cy3-conjugated donkey antirabbit antibody was used as the
secondary antibody. Nuclei were subsequently stained by Hoechst
33258 (1 μg/mL, Sigma) for 15 min in the dark. The coverslips were
mounted on glass slides with Immunon mounting medium (Shandon)
and imaged by fluorescence microscopy (Olympus BH2-RFCA,
Olympus) with a digital camera (Olympus DP70 digital microscope
camera, Olympus).
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■ RESULTS
The semisynthesis of α-syn site-specifically phosphorylated
within the C-terminus (residues 107−140) involved an NCL
reaction between the recombinant thioester α-syn(1−106)SR
and the synthetic peptide α-syn (A107C−140) phosphorylated
at Tyr-125. Because the primary sequence of α-syn does not
contain any cysteine residues, we mutated alanine residue 107
to a cysteine to allow the NCL reaction to occur with the
juxtaposed residue at position 106 being an unhindered residue
(Gly) (Scheme 1).
Generation of Semisynthetic pY125 α-Syn. Recombi-
nant α-syn(1−106)SR was expressed in E. coli utilizing the
intein approach, which exploits the mechanism of intein self-
splicing to generate recombinant proteins with a C-terminal
thioester (Scheme 3A).24 In the case of natural intein splicing, a
series of transthioesterification and succinimide formation
events that involve an arginine residue at the C-terminus of
the intein mediate the splicing of the intein and the linkage of
the N-extein and the C-extein by an amide bond.40 The
engineered mini-intein (Mxe GyrA) allows for splicing of the N-
extein as a thioester in presence of thiols. Briefly, truncated α-
syn(1−106) was expressed in fusion with the GyrA mini-intein
(Mxe GyrA) which contained a C-terminal hexahistidine
purification tag to facilitate purification from bacterial lysate.
Initially, we used the chitin binding domain from the
commercially available IMPACT system (New England
Biolabs) as a purification tag for the attachment of the fusion
protein to the chitin beads followed by splicing on the column
with 0.25 M MESNa and subsequent purification of the
thioester by reverse-phase HPLC. We then added a C-terminal
histidine tag on the intein to facilitate the purification of the
protein from larger volumes of E. coli lysates. The purification
procedure was therefore modified, and cell lysates were passed
through a Ni-NTA column to immobilize the fusion protein
Scheme 3. Semisynthesis and Characterization of Phosphorylated α-Syn Derivativesa
a(A) Expressed protein ligation (EPL) approach to generate WT α-syn and pY125 α-syn. The α-syn(1−106)SR fragment was generated using
intein-mediated thioester formation. MALDI-TOF analyses of (1) α-syn(1−106)SR (expected mass: 10 744 Da [M + H]). The synthetic peptides α-
syn (A107C−140) and α-syn(A107C−140)_pY125 were generated by Fmoc-based SPPS. MALDI-TOF analyses of (2) α-syn(A107C-140)_pY125
(expected mass: 3970 Da [M + H]). Full-length semisynthetic α-synA107C and α-synA107C_pY125 were generated by an NCL step between α-
syn(1−106)SR and synthetic peptide α-syn(A107C-140)_pY125 or α-syn(A107C-140). Radical desulfurization of the purified ligation product
generated pY125 α-syn and α-syn WT. The final purification step involved a cation-exchange chromatographic step. (B) MALDI-TOF analyses of
(3) α-synA107C_pY125 (expected mass: 14 573 Da [M + H]) and (4) pY125 α-syn (expected mass: 14541 Da ([M + H])). (C) Coomassie blue
stained SDS-PAGE analysis of the NCL reaction to generate pY125 α-syn. Lanes 1, 2, 3, and 4 represent α-syn(1−106)SR, ligation reaction after 45,
90, and 140 min, respectively.
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and remove undesired proteins (Scheme 3A). The α-syn(1−
106)SR was released by thiolysis with an excess of MESNa. The
protein thioester was then purified by RP-HPLC and
characterized by MALDI-TOF mass spectrometry and RP-
HPLC (Scheme 3A and Figure S3).
The peptide fragments α-syn (A107C−140) pY125 and α-
syn (A107C-140) WT, each with an N-terminal cysteine, were
generated by stepwise SPPS (Figures S1 and S2). The
expressed fragment α-syn(1−106)SR was then subjected to
two separate NCL reactions under denaturing conditions with
2 molar excess synthetic C-terminal peptides α-syn (A107C-
140) pY125 and α-syn (A107C-140) (Scheme 3A), generating
two variants of full length α-syn A107C selectively phosphory-
lated at Tyr-125 (pY125 α-syn) and the wild-type (WT)
protein, respectively. Hydrolyzed α-syn(1−106)−OH was
generated as a minor side product, even when the NCL
reaction was carried out at lower pH values. Due to the
coelution of α-syn(1−106)OH and the full-length protein by
reverse phase HPLC under all conditions tested in our
laboratory, we could not quantitatively assess the yield at
each step of the semisynthesis. The final yield of the purified
protein is 19% (Scheme 3C and Figure S5). Radical-initiated
desulfurization of Cys-107 in the ligated proteins re-established
the native Ala-107 residue in the phosphorylated variant of α-
syn and its wild-type counterpart with minimal loss of starting
material. A loss of 32 mass units from each protein was
observed by MALDI-TOF-MS in each protein, consistent with
the loss of a sulfur atom (Scheme 3B and Figures S6 and S8).
Separation of the ligated fragment from the hydrolyzed
thioester and excess C-terminal peptide was initially achieved
by using a combination of different purification methods,
including RP-HPLC, anion-exchange, liquid isoelectric focus-
ing, and size exclusion chromatography. Only a combination of
two or more of these techniques resulted in pure semisynthetic
proteins. However, this approach resulted in very low final
yield. Later, the ligation products were purified using cation-
exchange chromatography, which permitted single-step chro-
matographic separation of the full-length fragment, the
hydrolyzed thioester, the C-terminal peptide, and other
contaminants (Figure S9−11). Using optimized NCL, desul-
furization, and purification conditions, we obtained milligram
quantities of the purified ligated proteins (9 mg). In the case of
α-syn phosphorylated at Y125, MALDI-TOF analysis of the
purified products demonstrated a major peak with m/z = 14
Figure 1. Biochemical and biophysical characterization of semisynthetic WT and pY125 α-syn. (A) SDS-PAGE, RP-HPLC, and MALDI-TOF
analyses of the pure semisynthetic pY125 α-syn. MALDI analysis pY125 α-syn (expected mass: 14 541 Da ([M + H]), a sinapinic matrix adduct, is
also observed as well as the double-charged peak. (B) Western-blot analyses of WT and pY125 α-syn confirmed that the phosphorylated
semisynthetic protein could be detected by the anti-phosphorylated α-syn primary antibody, as well as by a nonphosphospecific antibody. (C)
Circular dichroism spectra of pY125 α-syn in the absence (circles) and presence (triangles) of POPG vesicles. Open and closed symbols indicate WT
recombinant α-syn and pY125 α-syn, respectively.
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545 corresponding to the desired [M + H+] ions (Figures 1A,
S6, and S8). Western-blot analysis using anti-α-syn and anti-
pY125 α-syn antibodies further confirmed the identity and
purity of the semisynthetic WT α-syn and pY125 α-syn
proteins (Figure 1B).
Semisynthetic pY125 α-Syn Adopts an α-Helical
Structure upon Membrane-Binding. The secondary
structure of the semisynthetic pY125 α-syn was investigated
using circular dichroism in solution (50 mM Tris buffer and
150 mM NaCl, pH 7.5) and in the presence of POPG vesicles
(with a lipid/protein mass ratio of 20:1). As shown in Figure
1C, pY125 α-syn exhibits a virtually identical CD spectrum to
that of the WT recombinant α-syn in solution (random coil)
and adopts an α-helical structure upon binding to lipid vesicles.
Phosphorylation at Y125 Does Not Alter the
Structure of Monomeric α-Syn. To determine the effect
of Y125 phosphorylation on the structural properties of
monomeric α-syn, 15N labeled A107C α-syn and A107C/
pY125 α-syn were generated for solution NMR studies (Figures
S12 and 13). The NMR spectra of the free proteins were
essentially identical and similar to the equivalent spectrum of
the WT protein (not shown), indicating that both A107C and
A107C/pY125 α-syn remain in the highly disordered ensemble
characteristic of this protein.41 To assess the potential influence
of phosphorylation on the transient long-range structure of the
protein, we collected paramagnetic relaxation data for
phosphorylated and unphosphorylated α-syn modified at Cys
107 by the spin label MTSL. The paramagnetic spin label
increases the relaxation rate and thus broadens the resonance of
any residue within ∼20 Å. Intramolecular contacts can thus be
discerned by measuring the intensity ratio of resonances in a
paramagnetically labeled sample to the equivalent resonances in
a diamagnetic control. Plots of the intensity ratio as a function
of residue number for A107C and A107C/pY125 α-syn, shown
in Figure 2A, reveal two interesting results. First, even in the
unphosphorylated sample, there is little indication of the
previously reported long-range contacts between the C- and N-
terminal regions of the protein.35 This observation is surprising,
but it suggests that position 107 may not be highly sensitive to
these contacts. However, there is a significant difference in the
data between the phosphorylated and unphosphorylated
proteins in the regions proximal to the labeling site. Residues
close to the labeling site are broadened because they are
covalently constrained to close proximity with the spin label,
resulting in a well (or minimum) around position 107. It has
been argued that the breadth of this well reflects the local
compactness of the protein. Despite the fact that only residues
prior to the position 107 in A107C/pY125 α-syn are 15N
Figure 2. NMR characterization of free and micelle-bound WT and pY125 α-syn. (A) Paramagnetic relaxation enhancement profiles for A107C
(upper panel) and A107C/pY125 (lower panel) α-syn, derived from the intensity ratios of equivalent resonances between 1H,15N HSQC spectra
collected with and without an attached spin-label. A ratio of 1 indicates no PRE effect, while smaller ratios indicated a PRE effect, resulting from the
proximity of the corresponding residue to the site of spin-label attachment. (B) Overlaid 1H,15N HSQC spectra of SDS micelle bound WT (black)
and A107C/pY125 (red) α-syn (upper panel) and plots of the normalized chemical shift changes between the two spectra as a function of residue
number (lower panel). The solid line in panel B is a three-residue average. Note that each red peak corresponds closely to a black peak, indicating
that the structures of the two variants are highly similar in the micelle-bound state. Black peaks without corresponding red peaks arise from residues
108 and beyond, where the semisynthetic A107C/pY125 protein is not 15N-labeled and therefore does not give rise to signals in this spectrum.
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labeled give rise to data, it is evident that the well around
position 107 is narrower for the phosphorylated protein. This
result indicates that, in the phosphorylated protein, the C-
terminal region samples a more expanded ensemble of
conformations.
Because the PRE data could not be used to monitor changes
in long-range contacts due to phosphorylation at position 125,
we also measured and compared the hydrodynamic radii of the
phosphorylated and unphosphorylated proteins using pulsed
field gradient NMR methods. The hydrodynamic radius of
A107C/pY125 α-syn was found to be identical, within
experimental error, to that of both A107C and WT α-syn,
indicating that no significant overall compaction or expansion
of the monomer occurs upon Y125 phosphorylation. These
observations contrast with observations made in the case of
S129 phosphorylation, where a significant degree of expansion
occurs.35
We also examined the potential effects of phosphorylation at
Y125 on the micelle-bound form of the protein; this form is
thought to closely resemble one of several membrane-bound
forms of the protein. We observed a high degree of overlap
between the 1H,15N-HSQC spectra of wild-type A107C/pY125
α-syn in the presence of SDS micelles (Figure 2B), indicating
that no gross structural changes in the protein occur upon
phosphorylation at Y125. To more closely assess the effects of
Y125 phosphorylation, we plotted the chemical shift changes
between the two spectra as a function of residue number
(Figure 2B). The results show that while the changes are
generally small (on the order of 0.01 ppm), they are larger than
those we observed for pS129.35 Furthermore, these changes
appear to be slightly greater in regions corresponding to the
center of each of the two previously characterized helices of the
micelle-bound form of the protein.42
Phosphorylation at Y125 Does Not Affect the
Fibrillization of α-Syn. Previously, work from our group
and others35,43 has shown that phosphorylation at S129 inhibits
the fibrillization of α-syn in vitro. To determine whether
phosphorylation at Y125 influences the aggregation properties
of α-syn, we optimized conditions for α-syn fibril formation at
low protein concentrations (15 μM) and compared the extent
and kinetics of fibrillization of semisynthetic pY125 α-syn to
those of the semisynthetic WT α-syn and recombinant WT
proteins. Each protein was incubated with agitation at 37 °C,
and the extent of fibrillization was assessed by ThT
fluorescence and TEM after 72 h of agitation. As evidenced
by the increase in ThT signal shown in Figure 3, WT and
pY125 α-syn form mature fibrils after 24 h of incubation. Next,
we assessed the amount of monomeric protein using a filtration
assay and used TEM to characterize the structural properties of
the aggregates formed by each protein. On the structural level,
Figure 3. Fibrillization of pY125 α-syn. (A) ThT fluorescence of recombinant WT and pY125 α-syn monitored over 48 h. (B) SDS-PAGE analysis
of the remaining WT and pY125 α-syn monomers prior to and after aggregation for 72 h and filtration through a 100 kD membrane. (C) TEM
images of WT and pY125 α-syn after 7 days of aggregation. The scale bar represents 500 nm. The images are representative of 5 independent
experiments. The scale bar represents 500 nm.
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both WT and pY125 α-syn formed mature fibrillar structures
(Figures 3C and S14). After filtration of the samples through a
100 kDa membrane filter, the amount of monomeric α-syn was
assessed by SDS-PAGE analysis. No significant amounts of
monomers were detected for WT and pY125 α-syn after 7 days
(Figure 3B). Together, these data suggest that phosphorylation
at Y125 does not alter the aggregation of α-syn.
pY125 α-Syn is Dephosphorylated within Minutes in
Vitro and in Vivo. To investigate the subcellular localization
in vivo, pY125 α-syn was microinjected into hippocampal
primary neurons at a concentration of 1 μM. Because
microinjected pY125 α-syn might be rapidly dephosphorylated,
we fixed the neurons either immediately or 30 min after
microinjection and probed for pY125 α-syn and total α-syn
using the appropriate antibodies. Interestingly, in the injected
cells, the signal for pY125 α-syn dramatically decreased within
30 min compared to the signal for WT α-syn (data not shown).
To confirm these observations and to test for rapid
dephosphorylation in vitro, a HeLa cell lysate was spiked with
pY125 α-syn and incubated for 0, 30, and 60 min. A loss of
signal from the phosphorylated protein but not from the total
α-syn protein was observed, indicating that pY125 α-syn is
completely dephosphorylated by endogenous phosphatases
within 30 min of incubation (Figure 4D). These results indicate
tight regulation of the phosphorylation state of α-syn at Y125
by endogenous tyrosine phosphatases. In these experiments,
dephosphorylation was effectively inhibited using sodium
orthovanadate, a general tyrosine-phosphatase inhibitor.
pY125 α-syn Is Localized in the Cytoplasm of
Mammalian Cells and Primary Neurons. Previous attempts
to characterize the possible effect of Y125 phosphorylation on
the subcellular localization of α-syn were unsuccessful, in part
due to a lack of pY125-specific antibodies that are suitable for
immunocytochemistry.18 In an attempt to overcome this
limitation, we generated an antibody specific for pY125 α-syn
and used it to immunolocalize of pY125 α-syn in HeLa cells
and rat hippocampal neurons. The pattern of pY125 α-syn
immunoreactivity produced by this antibody was compared
with the pattern obtained using a commercially available
antibody from BD Pharmingen. For these experiments, we first
identified conditions that prevent rapid dephosphorylation of
pY125 α-syn. Previous reports indicated that pY125 α-syn is
detectable in HEK293 cells that overexpress WT α-syn upon
treatment with pervanadate.39,44 We validated these findings
and found by western-blot analysis of lysates from HEK293 and
HeLa cells overexpressing human WT α-syn that treatment
with pervanadate results in the upregulation of pY125 α-syn in
these cells (Figure 4C). In cells overexpressing WT α-syn, but
Figure 4. Dephosphorylation and detection of pY125 α-syn in cells. (A) Confocal images of HeLa cells transfected with WT α-syn plasmid and
treated or not with pervanadate for 30 min. The scale bar represents 20 μm. Subsequently, the cells were fixed and stained with the indicated
antibodies (respectively, rabbit anti-α-syn from Abcam ab51252 and mouse anti-pY125 α-syn from BD Pharmingen). (B) Detection of pY125 α-syn
in primary neurons. Confocal images of rat hippocampal neurons microinjected with 1 μM pY125 α-syn (25 fl/injection) together with the visible
marker dye Fast Green (100 μg/mL) to identify the injected cells; the cells were treated with medium containing pervanadate for 30 min.
Subsequently, the cells were fixed and stained with the indicated antibodies (respectively rabbit anti-α-syn from Abcam ab51252 and mouse anti-
pY125 α-syn from BD Pharmingen). (C) Immunoblots of HEK and HeLa cell lysates untreated or treated with pervanadate for 0, 5, 10, and 20 min.
The membranes were probed with total α-syn and pY125-specific antibodies (respectively, rabbit anti-α-syn ab51252 from Abcam and mouse anti-
pY125 α-syn from BD Pharmingen). D: Immunoblots of pY125 α-syn dephosphorylated from HeLa cell lysate. Membranes were probed with total
α-syn and pY125-specific antibodies. The dephosphorylation was inhibited using different concentrations of sodium orthovanadate. (E)
Immuboblots of the subcellular fractionation of HEK cells overexpressing WT α-syn and treated with pervanadate for 20 min. Markers for
cytoplasmic, membrane, and nuclear fraction were used to assess for the purity of each fractions (Hsp90α, calnexin, and PARP-1).
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not the mutant Y125F α-syn, we observed a significant increase
in the level of pY125 α-syn when the duration of treatment
with pervanadate was increased. Nonspecific bands of higher
molecular weight were also detected with both the commercial
(BD Pharmingen) and homemade anti-pY125 α-syn antibodies
after pervanadate treatment (Figure S15). This precludes the
use of these antibodies to accurately assess in more detail the
subcellular localization of pY125 α-syn in specific cellular
organelles. We were able to partially circumvent this problem
by studying the subcellular localization of pY125 α-syn in HeLa
cells overexpressing α-syn (Figure 4A). Quantification of the
average fluorescence intensity of 65 cells (data not shown)
treated with pervanadate showed that the increasing levels of
cytosolic pY125 α-syn correlated well with increasing α-syn
levels, and indicated a predominantly cytosolic localization of
pY125 α-syn. We did not observe pY125 α-syn immunor-
eactivity in the nucleus, nor was any cytosolic increase in pY125
α-syn immunoreactivity observed in HeLa cells overexpressing
the mutant Y125F α-syn (Figure S16). When semisynthetic
pY125 α-syn was microinjected into rat hippocampal neurons
at a concentration of 1 μM, it showed a cytoplasmic
distribution similar to the distribution of WT α-syn
immunoreactivity in HeLa cells (Figure 4B). To more
accurately assess the subcellular localization of pY125, we
preformed subcellular fractionation studies on HEK 293T cells
overexpressing α-synuclein in the presence and absence of
pervanadate. Using this approach, we can demonstrate
conclusively that pY125 localizes mainly in the cytosolic
fraction and to a small extent in the membrane fraction,
consistent with the results from immunocytochemistry (Figure
4E).
Phosphorylation at Y125 Does Not Block the
Phosphorylation at S129 and S87 in Vitro and Vice
Versa. The proximity of the three C-terminal tyrosine residues
in α-syn suggests the possibility that the phosphorylation of one
of these residues may trigger or modulate the extent of
phosphorylation at the other residues. In a recent study, Y125
phosphorylation was suggested to protect against α-syn
toxicity.18 Using a transgenic Drosophila model overexpressing
the S129D phosphomimetic mutant of human α-syn in retinal
and dopaminergic neurons, Chen et al. demonstrated that
coexpression of Shark, a Drosophila homologue of the human
tyrosine kinase Syk, which was previously reported to efficiently
(although nonspecifically) phosphorylate α-syn at Y125,45
significantly alleviates neurodegeneration due to S129D α-syn
expression. To investigate potential cross-talk between Y125
and S129 phosphorylation sites, pY125 α-syn was either
incubated with PLK3 or CK1 kinase, which are known to
phosphorylate α-syn specifically and efficiently at S129 (PLK3)
or at S87 and S129 (CK1). Phosphorylation at Y125, S129, and
S87 was detected using the appropriate phosphospecific
antibodies and confirmed by MALDI-TOF MS (Figure
5A,B). These results indicated that phosphorylation of α-syn
at Y125 does not prevent recognition of the protein by PLK3 or
CK1, affect the subsequent phosphorylation of pY125 α-syn at
S129 and S87, or prevent recognition of the double-
phosphorylated species (pY125/pS87 and pY125/pS129) by
the appropriate antibodies. To determine whether phosphor-
ylation at Y125 influences S129 phosphorylation by endoge-
nous kinases, we assessed the levels of pS129 in HeLa and
HEK293 cells before and after treatment with pervanadate.
Despite the significant increase in pY125 α-syn levels observed
upon treatment with pervanadate, we did not observe any
significant changes in pS129 levels (Figure 6).
A recent study by Chen and colleagues suggested that
phosphorylation at S129 does not affect the tyrosine
phosphorylation of α-syn.18 However, these results were
based on expression of a phosphomimetic mutant (S129D)
that does not reproduce all aspects of phosphorylation at this
site.35 Therefore, we sought to determine whether prior
Figure 5. Phosphorylation of pY125 and pS129 α-syn. (A) Immunoblots of pY125 α-syn phosphorylated by CK1 and PLK3. Membranes were
probed using pS129, pY125, and α-syn antibodies. (B) MALDI-TOF-MS analysis of the phosphorylation reaction after 12 h. (C) Immunoblots of
pS129 α-syn phosphorylated by Syk, Lyn, Fyn, c-Src, and c-Fgr. Membranes were probed for pY125, pS129, and α-syn immunoreactivity. (D)
MALDI-TOF analysis of pS129 α-syn phosphorylated by (a) Syk, (b) Lyn, (c) Fyn, (d) c-Src, (e) and c-Fgr (f) after 14 h of reaction. In all MALDI-
TOF-MS spectra, the symbol n indicates the peak corresponding to the starting material, and the numbers above the other peaks correspond to the
number of phosphorylation events, which were each detected by a +80 Da mass shift. The asterisk indicates a sinapinic acid matrix adduct.
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phosphorylation at S129 effects further phosphorylation at
Y125 by the nonreceptor tyrosine kinases Syk and members of
the Src family (Lyn, Fyn, c-Fgr, and c-Src), which have been
previously shown to phosphorylate tyrosine residues in the C-
terminus of α-syn. The protein was first quantitatively
phosphorylated using PLK3, purified by reverse-phase HPLC,
and incubated at 3 μM for 14 h at 30 °C in the presence of 100
nM of each individual tyrosine kinase. Western-blot and
MALDI-TOF-MS analyses (Figure 5C,D) showed the same
efficiency and site-specificity of phosphorylation by these
kinases as reported in previous in vitro studies. Of these
kinases, Syk is by far the most efficient at phosphorylating α-syn
with a reported Kcat/Km of around 30; it also phosphorylated
multiple tyrosines within the C-terminal region of α-syn.39,45
We consistently observed phosphorylation at Y125 and at two
other sites by MALDI-TOF MS (Figure 5D, part b). The other
kinases were more specific but lacked efficiency. For example,
the Kcat/Km for Lyn is around 0.5. Most importantly, we
observed that S129 phosphorylation did not block the activity
of any of the tyrosine kinases. As a control, WT α-syn was
incubated under the same conditions, and a similar
phosphorylation pattern was obtained (data not shown).
Western-blot-based detection of Y125 phosphorylation ap-
peared to be more sensitive than MALDI-TOF-MS because
pY125 α-syn could be detected in all of the enzymatic reactions
(Figure 5C). Together, these data suggest that S129
phosphorylation of α-syn does not interfere with further
modifications of the protein by tyrosine kinases. Moreover,
because the consensus recognition sequences of tyrosine
kinases such as Syk include acidic residues,46 pS129 might act
to stabilize the electrostatic interactions between the kinases
and α-syn.
We performed a similar experiment aimed at determining
whether phosphorylation at S87, another disease-related
phosphorylation site within α-syn that was recently identified
by our group,34 influences the recognition and processing of α-
syn by the soluble tyrosine kinases mentioned above. We
observed that phosphorylation of α-syn at S87 does not
significantly influence the protein’s activity as a substrate for the
nonreceptor tyrosine kinases Syk, Fyn, Ly, c-Fgr, and c-Src or
the site-specificity of its phosphorylation by these enzymes
(Figure S17).
■ DISCUSSION
Recent studies indicate that α-syn phosphorylation at serine
residues S87 and S129 can dramatically influence α-syn
structure,34,35 turnover,47 membrane binding,34,35 aggrega-
tion,34,35 and protein−protein interactions.48 Notably, phos-
phorylation at S87 and S129 have emerged as a defining
hallmark of PD and other synucleinopathies.49,50 The use of
phosphomimetic mutations (S→E/D) combined with the
identification of kinases that specifically phosphorylate α-syn
in vitro and in vivo has facilitated detailed studies aimed at
investigating the structural and functional consequences of
phosphorylation of the protein at these residues in vitro and in
vivo.18,20,38,51−55 In addition to serine residues, α-syn has also
been shown to undergo phosphorylation at its C-terminal
tyrosine residues Y125, Y133, Y136 in vitro, with a preference
for Y125 as the major phosphorylation site.39,44,45,56 However,
only phosphorylation at Y125 has been detected in vivo.18
Several kinases have been reported to phosphorylate tyrosine
residues in the C-terminus of α-syn. However, all known
kinases are either inefficient or lack specificity to phosphorylate
α-syn at specific tyrosine residues in its C-terminus. The
tyrosine kinase Syk phosphorylates α-syn at multiple tyrosine
residues (Y125, Y133, and Y136).45 In contrast, Fyn, Lyn, c-
Fgr, and c-Src phosphorylate α-syn specifically at Y125, but
these kinases are less efficient.45 The lack of specificity and
efficiency of tyrosine phosphorylation of α-syn has hampered
efforts to obtain homogeneous preparations of phosphorylated
α-syn and to elucidate the structural and functional
consequences of phosphorylation at Y125. Unlike phospho-
serine and phospho-threonine, which in some cases can be
mimicked by serine → glutamate or aspartate substitutions,
there are no natural amino acids that can mimic phospho-
tyrosine. Inspired by the pioneering work of Muir and Cole on
the use of expressed protein ligation to study the effect of site-
specific phosphorylation and other post-translational modifica-
tions,24 we developed, for the first time, an efficient
semisynthetic approach based on a one-pot native chemical
ligation and desulfurization followed by a single chromato-
graphic purification step for the production of pY125 α-syn.
This strategy enabled us to obtain preparations of α-syn protein
site-specifically modified at single or multiple residues within
the C-terminal region comprising residues 107−140, the region
that contains the majority of the reported PTMs of the protein.
Using this approach, we were able to obtain milligram
quantities of semisynthetic WT and pY125 α-syn and to
carry out detailed studies aimed at elucidating the effect of this
modification on the structure, membrane binding, aggregation,
and subcellular localization of α-syn.
The results presented here demonstrate that phosphorylation
at Y125 does not significantly alter the structure of monomeric
α-syn in solution (Figures 1B and 2). Although the hydro-
dynamic radius of pY125 α-syn is virtually identical to that of
the wild-type protein, the paramagnetic relaxation data
presented here indicate that the C-terminal region of pY125
α-syn samples a more expanded ensemble of conformations
than the wild-type protein. Interestingly, these observations
contrast with the case of S129 phosphorylation, where a
significant degree of expansion occurs.35 Phosphorylation at
Y125 did not interfere with the ability of α-syn to form an α-
helical structure upon binding to synthetic phosphatidylglycerol
Figure 6. Phosphorylation of pY125 α-syn and pS129 α-syn.
Immunoblots of HeLa cells overexpressing WT α-syn and treated
with pervanadate for 0, 5, 10, and 20 min. Membranes were probed
with pS129 and pY125 α-syn and WT α-syn antibodies.
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(POPG) or SDS micelles as assessed by CD spectroscopy.
These results are consistent with previous observations
regarding pS129 and with the fact that both S129 and Y125
lie outside the region involved in α-syn binding to membranes.
However, the 1H,15N-HSQC spectra of the protein reveal small
structural changes that are larger than those observed for the
case of pS129.35 Furthermore, the structural changes in the
protein that result from Y125 phosphorylation appear to be
slightly greater in regions corresponding to the centers of each
of the two previously characterized helices of the micelle-bound
form of the protein.57 Thus, while phosphorylation at Y125
does not result in large-scale structural changes in the micelle-
bound form of the protein, it may cause slight rearrangements
of the two micelle-bound helices. Such small changes may be
consistent with results that indicate that modifications
occurring in the C-terminal tail of the protein can influence
the N-terminal lipid-binding domain.58
Previous studies by Negro et al. showed that coincubation of
α-syn with Syk kinase inhibits α-syn aggregation in vitro.45
Coexpression of Syk and α-syn was also reported to inhibit α-
syn oligomerization and inclusion formation in cell culture45
and in Drosophila expressing Shark, the fly homologue of Syk.18
However, it is difficult to discern the relative contribution of
phosphorylation at Y125 in these studies, because the Syk
kinase phosphorylates all three C-terminal tyrosine residues
(Y125, Y133, and Y136) to different extents. In subsequent
studies by Negro and colleagues, it was reported that the
addition of other tyrosine kinases (Lyn and c-Fgr) did not
influence the aggregation of α-syn in vitro.45 However, the
significantly reduced efficiency of these kinases for the
phosphorylation of α-syn makes it difficult to draw any
conclusions regarding the effect of phosphorylation at Y125 on
α-syn aggregation and fibrillization. In this work, the availability
of semisynthetic pY125 α-syn allowed us to address this
question directly for the first time. WT α-syn and semisynthetic
pY125 α-syn exhibited similar aggregation properties as
discerned by TEM and ThT fluorescence, demonstrating that
pY125 α-syn behaves similarly to the recombinant protein
produced in E. coli, unlike phosphorylation at S129, which
inhibits α-syn fibrillization. Interestingly, pY125 α-syn exhibited
similar aggregation properties as WT α-syn, consistent with the
NMR results demonstrating that phosphorylation at Y125
induces only subtle structural changes on monomeric α-syn.
The availability of semisynthetic pY125 α-syn provided
unique opportunities to assess the subcellular localization of
pY125 α-syn and to explore the potential cross-talk between
phosphorylation at S129 and Y125. Recent studies by Chen et
al. suggested that Y125 phosphorylation may protect against α-
syn toxicity by decreasing α-syn phosphorylation at S129.18 To
investigate possible cross-talk between phosphorylation at S129
and Y125, we combined semisynthetic approaches and
enzymatic phosphorylation assays. Employing optimized
procedures for the in vitro phosphorylation of α-syn, we used
semisynthetic pY125 α-syn to examine the effect of
phosphorylation at Y125 on S129 phosphorylation by
subjecting pY125 α-syn to phosphorylation by kinases that
phosphorylate α-syn efficiently at S129 (PLK3) and/or S87 and
S129 (CK1).35,38 To determine whether phosphorylation at
S129 influences Y125 phosphorylation, we prepared pS129 α-
syn by in vitro phosphorylation with PLK338 and examined the
extent of Y125 phosphorylation (pS129/pY125) by the
tyrosine kinases Fyn, Lyn, Src, c-Fgr, and Syk.39,44,45,56 Our
results demonstrate that phosphorylation at Y125 does not
attenuate α-syn phosphorylation at S129 or S87 in vitro and
vice versa. These findings are consistent with the results of
studies from Feany and colleagues in Drosophila suggesting that
S129 phosphorylation of α-syn does not influence Y125
phosphorylation. The levels of pY125 α-syn were similar in
flies overexpressing WT, S129A, or S129D, suggesting that
S129 phosphorylation does not influence phosphorylation at
Y125. This study confirms these findings in mammalian cells
(HeLa and HEK 293T), where no changes in pS129 levels were
observed after treatment with phosphatase inhibitors that
significantly enhance pY125 α-syn levels.
The lack of significant interest in phosphorylation of α-syn at
Y125, compared to phosphorylation at S87 and S129, can be
attributed to difficulties in detecting significant levels of pY125
α-syn in human brain tissues and lack of evidence for a direct
correlation between pY125 α-syn levels and disease pro-
gression. Proteomic and mass spectrometry analyses of α-syn
from Lewy bodies failed to detect phosphorylation at Y125.49
The rapid dephosphorylation of α-syn in post-mortem tissues
may explain the limited success of previous studies in detecting
pY125 α-syn in human brains and by biochemical analysis of
brain-derived materials using mass spectrometry. Due to the
dynamic regulation of tyrosine phosphorylation in vivo,
detection of α-syn phosphorylation at Y125 appears to be
dependent on the use of tyrosine phosphatase inhibitors or on
the time elapsed prior to post-mortem analyses. Recently, Y125
phosphorylation was shown to occur both in human and
Drosophila brains, and pY125 α-syn levels were reported to
decrease with aging and in PD brains, suggesting a possible
protective role for this modification.18 Interestingly, in the
presence of phosphatase inhibitors, 30% of α-syn in Drosophila
appears to be phosphorylated at Y125 supporting the role of
Y125 phosphorylation in modulating α-syn properties. In this
study, we showed that, upon addition of pY125 α-syn to cell
lysates or microinjection into primary neurons, pY125 α-syn is
almost completely dephosphorylated within 5 min. This effect
is blocked by the presence of pervanadate. These results are
consistent with a very rapid dephosphorylation of α-syn both in
vitro and in vivo. Phosphorylation at Y125 appears to be tightly
regulated such that the levels of pY125 α-syn are maintained at
very low levels but increase significantly in cell culture, primary
neurons, and brain tissues, upon treatment with the
phosphatase inhibitor pervanadate.18,39,44 Together, these
studies demonstrate that α-syn undergoes phosphorylation at
Y125 in vivo and suggest that experiments aimed at evaluating
and correlating specific PTMs with disease progression must
take into account the stability and dynamics of these
modifications, and that the protocols used for the analysis
and preparation of samples must be modified accordingly.
Nakamura et al. reported that the levels of pY125 α-syn
increase by approximately 15-fold within the first few minutes
in response to hyperosmotic stress, but then decline rapidly
after 10 min. These observations indicate the existence of
efficient dephosphorylation mechanisms that regulate pY125 α-
syn levels.59 However, the identities of the phosphatases
responsible for regulating pY125 α-syn phosphorylation remain
unknown. The availability of semisynthetic pY125 α-syn as a
substrate should facilitate the development of assays to screen
focused libraries of tyrosine phosphatase inhibitors and identify
natural phosphatases that are involved in regulating Y125
phosphorylation in vivo. To prevent the rapid dephosphor-
ylation of pY125 α-syn, we will replace phosphotyrosine by
nonhydrolyzable phosphonate analogues60,61 that, once in-
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corporated into α-syn, will render it resistant to phosphatase
activity.62 Cole and colleagues have successfully introduced
nonhydrolyzable tyrosine analogues into proteins using ex-
pressed protein ligation strategies and demonstrated their utility
to investigate the role of tyrosine phosphorylation in regulating
the activity of different tyrosine phosphatases and their
interaction with other proteins.29,62−66
Whether phosphorylation at Y125 plays an important role in
regulating α-syn aggregation and toxicity in vivo remains
unknown. This question can only be answered by experimental
conditions that permit site-specific regulation of phosphor-
ylation at Y125 in vivo. To determine the functional
consequences of Y125 phosphorylation, Feany and colleagues
overexpressed WT α-syn, and mutant (α-synYF) in which all C-
terminal tyrosines were mutated to phenylalanine (Y125F/
Y133F/Y136F), and compared the effects of the mutations on
α-syn aggregation, toxicity, and locomotor deficit in flies. The
mutant (α-synYF) exhibited enhanced toxicity and caused a
significant reduction in climbing ability compared to flies
overexpressing the wild-type protein. Additionally, over-
expression of the Shark kinase, the Drosophila homologue of
Syk, increased the levels of pY125, decreased oligomer
formation, and rescued the neurotoxicity of WT α-syn and of
the more toxic S129 phosphomimetic S129D. It is important to
note that, in both approaches, the three tyrosines were either
mutated or phosphorylated to different extents, making it
difficult to decipher the effects of selective modification at
Y125. Identification and expression of the kinases that allow
selective modification of pY125 and/or coexpression of such
kinases with Y133F/Y136F is crucial for gaining insight into the
role of Y125 phosphorylation in regulating α-syn aggregation
and toxicity in vivo. The availability of semisynthetic pY125 α-
syn and our improved understanding of the dynamics of Y125
phosphorylation should aid in the development of assays to
identify the natural kinases and phosphatases involved in the
regulation of Y125 phosphorylation and will facilitate a
quantitative evaluation of the extent of pY125 α-syn during
disease progression.
■ CONCLUSIONS
We recently reported a semisynthetic approach that enabled
site-specific modification of the N-terminus of α-syn and used
this approach to prepare and characterize an α-syn form that is
monoubiquitinated at lysine 6.30 In this study, we describe a
general and efficient semisynthetic strategy that enables the
site-specific introduction of single or multiple PTMs of α-syn
and the preparation of homogeneously modified forms of α-syn
at its C-terminus in milligram quantities. These two approaches
make it possible to prepare all the known disease-associated
PTMs of α-syn, except pS87, and to study potential cross-talk
between these modifications. These advances have allowed us
to investigate for the first time the effect of selective
phosphorylation at Y125 α-syn on the structure, aggregation,
membrane binding, and subcellular localization of the protein.
In addition, these advances provide unique opportunities to
investigate PTM-dependent protein−protein interactions in-
volving α-syn and to study the cross-talk between different
PTMs. Furthermore, the availability of these proteins is crucial
for advancing current research programs with the following
aims: (1) characterization of PTMs in humans and in animal
models of PD, (2) development of biomarkers and target
identification, and (3) development of sensitive assays for the
detection and quantitative assessment of specific PTMs in vivo
and in biological fluids. Therefore, the development of these
semisynthetic strategies represents an important advance
toward unraveling the roles of PTMs in determining α-syn
structure, aggregation, and functions in health and disease. We
hope that this work will encourage other research groups to
pursue similar approaches to elucidate the role of PTMs in
regulating the function of other proteins, particularly proteins
linked to neurodegenerative diseases.
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